Skye Bioscience (SKYE) Osake Kurssi

Skye Bioscience Inc is a US-based company operating in Biotechnology industry. The company is headquartered in San Diego, California and currently employs 11 full-time employees. The company went IPO on 2014-02-24. Skye Bioscience, Inc. is a biopharmaceutical company. The firm is focused on the discovery, development and commercialization of a class of cannabinoid derivatives to modulate the endocannabinoid system. The firm develops cannabinoid derivatives that have the potential to treat ophthalmic disorders and other diseases with unmet needs. The firm's lead product candidate, SBI-100 OE, is being developed for the treatment of glaucoma and ocular hypertension. The first-in-human Phase I trial of SBI-100 OE is being conducted in healthy volunteers in Australia to evaluate this drug candidate's safety, tolerability, pharmacokinetics and pharmacodynamics. The company is also focused on developing different formulations of SBI-200. Early studies of SBI-200 demonstrated analgesic, anti- inflammatory, anti-fibrotic and anti-seizure properties, including the potential treatment and management of several eye diseases, such as uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy.